The two companies have been working together since 2017, with Takeda pledging $100 million to help GammaDelta advance its cell therapy platform as part of a "build-to-buy" arrangement. The ...

Beth Marsh will lead commercialization for Neurotech, which gained FDA approval for its eye disease therapy. Neurotech in May ...

Before Plump joined Takeda, the company was a small-molecule ... microbiome-based medicines, multiple cell therapy platforms, plasma-derived therapies and vaccines. Now, they are back down to ...

BBM will work together with Takeda China to accelerate the rapid implementation of this innovative therapy. In the future ...

Takeda (TAK) Canada announced that Health Canada has expanded the marketing authorization for HyQvia for chronic inflammatory demyelinating polyneuropathy as maintenance therapy after ...

BBM will work together with Takeda China to accelerate the rapid implementation of this innovative therapy ... human coagulation FIX gene into liver cells of patients. Then, coagulation FIX ...